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Abstract
One aim for an HIV vaccine is to elicit neutralizing antibodies (Nab) that can limit replication of genetically diverse viruses
and prevent establishment of a new infection. Thus, identifying the strengths and weaknesses of Nab during the early
stages of natural infection could prove useful in achieving this goal. Here we demonstrate that viral escape readily occurred
despite the development of high titer autologous Nab in two subjects with acute/early subtype C infection. To provide a
detailed portrayal of the escape pathways, Nab resistant variants identified at multiple time points were used to create a
series of envelope (Env) glycoprotein chimeras and mutants within the background of a corresponding newly transmitted
Env. In one subject, Nab escape was driven predominantly by changes in the region of gp120 that extends from the
beginning of the V3 domain to the end of the V5 domain (V3V5). However, Nab escape pathways in this subject oscillated
and at times required cooperation between V1V2 and the gp41 ectodomain. In the second subject, escape was driven by
changes in V1V2. This V1V2-dependent escape pathway was retained over time, and its utility was reflected in the virus’s
ability to escape from two distinct monoclonal antibodies (Mabs) derived from this same patient via introduction of a single
potential N-linked glycosylation site in V2. Spatial representation of the sequence changes in gp120 suggested that
selective pressure acted upon the same regions of Env in these two subjects, even though the Env domains that drove
escape were different. Together the findings argue that a single mutational pathway is not sufficient to confer escape in
early subtype C HIV-1 infection, and support a model in which multiple strategies, including potential glycan shifts, direct
alteration of an epitope sequence, and cooperative Env domain conformational masking, are used to evade neutralization.
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Introduction
The current AIDS pandemic is the result of genetically diverse
viral subtypes and circulating recombinant forms (CRFs) of HIV-1
group M, of which subtypes A, C, and D account for a majority of
infections worldwide [1,2]. A key source of this genetic diversity is
the viral env gene, which encodes the envelope (Env) glycoproteins,
gp120 and gp41 (reviewed in [3]). On the virion, monomers of
non-covalently associated gp120 and gp41 subunits trimerize to
form ‘spikes’, and together these facilitate entry into a target cell.
Env has a complex conformation and undergoes substantial
rearrangements in both subunits upon gp120 binding to CD4 and
coreceptor [4,5,6]. Env also contains the principal targets for
neutralizing antibodies (Nab) [7,8], and epitopes are targeted in
both Env subunits [9]. However, many potential neutralization
targets are transiently or not exposed on the trimeric form of
virion-associated Env, including the V3 domain, CD4-induced
epitopes, and the CD4 binding site [10,11,12]. Despite these
limitations, most HIV-1 infected patients develop robust Nab
responses against their autologous virus, particularly those infected
with subtype C [13,14,15,16,17,18,19].
To confer potent and broad neutralization, it is expected that an
epitope will need to possess at least four properties: (i) exposure on
the virion-associated native Env trimer, (ii) conservation across
diverse HIV-1 variants, (iii) immunogenicity, and (iv) lack of
autoreactivity. To date, there are no epitopes that meet these
criteria. However, our knowledge of the epitopes that are
recognized by Nab during natural infection with diverse HIV-1 is
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targeted by the initial autologous Nab response, what proportion of
these epitopes is strain-specific or shared, how antigenicity differs
between patients or viral subtypes, or what the predominant escape
mechanisms are. Furthermore, there is mounting evidence that at
least some of these parameters differ between HIV-1 subtypes
(reviewed in [20]). We, and others, have characterized the
autologous Nab response as it first develops, and have observed
high titers of autologous Nab activity against the infecting strain in
most (but not all) patients [13,14,15,16,17,18,19]. In addition we
have reported higher Nab titers in subtype C infected patients
compared to subtype B infected patients that were evaluated in
parallel, prompting our group and others to propose that there are
differences in antigenicity between subtype B and C Envs
[15,20,21,22]. Recent studies honed in on regions that could be
involved in early subtype C autologous Nab responses, and these
included the V1V2 hyper-variable domain and the C3 to V4 sub-
region of gp120 [23]. However, these regions could not account for
all of the Nab activity present in patient plasma, suggesting the
involvement of additional determinants. Furthermore, we have
demonstrated that both V1V2-dependent and -independent
pathways are utilized for escape from Nab during chronic subtype
C infection [24]. In addition, we have shown a strong association
between mutations in the a2 helix region of C3 and neutralization
resistance, although these mutations did not directly alter
neutralization sensitivity when transferred between sensitive and
resistant Envs from linked transmission partners [25].
Temporal studies of HIV-1 have demonstrated that HIV-1
undergoes recurrent cycles of escape from autologous Nab
[17,19,26,27], and escape also occurred during infection with a
chimeric SIV-HIV-1 (SHIV) virus in response to vaccine-induced
Nab [28]. Yet, our knowledge of the specific molecular events that
lead to escape remains incomplete. Shifting carbohydrate moieties
in and around the outer surface of gp120, as well as changes in the
hyper-variable domains, have been proposed as general mecha-
nisms used by HIV-1 and SHIV to alter neutralization epitopes,
although most of these studies are based on subtype B Envs. Nab
escape in SHIV-infected macaques has been shown to involve
glycan changes in the V1, V2, and V3 domains, perhaps by
shielding conserved epitopes such as the CD4 binding site
[29,30,31]. Consistent with this finding, a recent study identified
V1V2 as the major determinant of strain-specific autologous Nab
in macaques infected with two different strains of SHIV [32], and
this domain was also shown to be the principal determinant of
inherent Nab resistance for HIV-1 strain JRFL [10]. Subtype B
HIV-1 can also escape from autologous Nab by shifting N-linked
carbohydrates on the outer domain of gp120 with little
involvement of V1V2 [17]. Others have demonstrated that
subtype B viral escape could also occur in the absence of frank
changes in glycosylation, with no clear mutational pattern
emerging [33]. In experimental SIVmac infection, the emergence
of N- and O-linked carbohydrates in the V1 and V4 hyper-
variable domains has been shown to confer escape from
autologous neutralization [34,35,36]. Furthermore, the presence
of specific glycans in V1 reduced the immunogenicity of SIVmac
in the context of an experimental infection [37]. Taken together,
these studies hint at the complexity of HIV-1 neutralization and
escape, but also suggest that common themes may exist.
Thus, unlike cytotoxic T lymphocyte (CTL) epitopes and their
escape mutations, which are frequently predicted by the
association of viral sequence polymorphism and HLA alleles,
Nab epitopes and escape pathways in Env can be inherently
difficult to identify based on sequence alone. We have therefore
undertaken a molecular approach to define these in subtype C
HIV-1 Env during early infection. Using a pseudovirus-based
assay that facilitates evaluation of individual, patient-derived Envs,
we analyzed the neutralizing ability of longitudinal plasma samples
against contemporaneously-derived, autologous Envs from two
subtype C seroconvertors who generated potent Nab against the
infecting Env. Sequential neutralization escape variants emerged
in both patients, and we used Env domain exchange and site-
directed mutagenesis approaches to map the pathways involved in
Nab escape at multiple time points throughout the first two years
of infection. Nab escape in these two patients was driven by V1V2-
dependent and -independent pathways, and these pathways
exhibited different levels of stability over time. Yet, spatial
representation of the sequence changes in gp120 indicated that
immune pressure was directed at the same Env regions in both
subjects. The derivation of autologous monoclonal antibodies
(Mabs) from one patient demonstrated how a single potential
glycan change in V1V2 afforded simultaneous resistance against
multiple antibodies. These studies therefore provide a detailed look
at Nab escape in subjects recently infected with the most
predominant subtype worldwide, and demonstrate that the
flexibility of Env facilitates the use of multiple mechanisms.
Results
Continuous cycles of neutralization escape occur
throughout early subtype C infection
We previously demonstrated that 9 out of 11 subtype C infected
subjects from the ZEHRP cohort developed robust autologous
Nab responses against the infecting Envs, with 50% inhibitory
(IC50) titers often exceeding 1:3,000 within the first few months of
infection [15]. For two of the subjects who developed potent
autologous Nab and were identified as viral p24 antigen positive
(Table 1), we sampled the emerging quasispecies by single genome
PCR amplification, cloning, and sequencing of biologically
functional env genes from longitudinal plasma and PBMC DNA
samples. For both subjects, the 0-month Envs were cloned at the
first seropositive time point estimated to be within 48 days of
infection, and longitudinal timing was calculated in months from
Author Summary
A significant obstacle to developing an HIV vaccine is the
potential for the virus to escape from the immune
response induced by immunization. We previously showed
that subjects in a Zambian cohort developed potent
neutralizing antibody responses shortly after becoming
infected by subtype C HIV-1, and here we have extended
those findings to demonstrate that cycles of viral escape
occurred in two of these subjects despite a potent
immune response. We investigated the determinants of
immune escape, and found that a single common
mutational pathway was not sufficient to facilitate viral
escape. Instead, we demonstrate that multiple strategies,
including potential changes in glycosylation pattern, direct
alteration of an epitope sequence, and cooperative
envelope interactions, were used independently or to-
gether to evade neutralization. We also recovered
individual monoclonal antibodies from one of the subjects
and found that a single mutation can confer escape from
different neutralizing antibody specificities. The studies
demonstrate the remarkable flexibility of subtype C HIV-1,
and suggest that the envelope glycoproteins are uniquely
equipped to adjust to the specific properties of the
immune response in each newly infected host.
Subtype C HIV-1 Nab Escape
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over the first two years of infection were evaluated. A subset of
Envs was chosen to represent the diversity of the circulating
quasispecies at each time point (see arrows in Fig. S1A and B), and
was evaluated for sensitivity to neutralization by each contempo-
raneous (simultaneously collected) plasma sample using the JC53-
BL (Tzm-bl) pseudovirus assay [15,24,25]. The IC50 Nab titer for
each plasma-Env combination was calculated from each virus
infectivity curve using a growth function. Fig. 1 shows that the
median IC50 titer of the 0-month Envs (designated according to
the first seropositive time point; see Table 1) was higher than the
contemporaneous Envs at each time point, indicating repeating
cycles of neutralization resistance. This difference in median IC50
titer was statistically significant at all time points for 185F.
However, for 205F, the median IC50 titer differed significantly at
only two time points, probably due to the wide range of Nab
sensitivities observed for the contemporaneous Envs of this subject
(Fig. 1B). Nevertheless, Nab-resistant variants were present at each
time point and these were neutralized by subsequent plasma
samples, indicating continued induction of a de novo Nab
response (data not shown).
Plasma Nab in subjects 185F and 205F possesses
moderate breadth against heterologous Envs
To gauge whether breadth developed within the window of
evaluation, cross-neutralizing activity of a single plasma sample
from subject 185F (23-months) and subject 205F (20-months) was
measured against heterologous 0-month subtype C Envs from six
other subjects in the same cohort (Fig. 2). Consistent with previous
studies of early subtype C infection [15,16], Nab in 185F and 205F
was mostly strain-specific. However, each of these plasma samples
neutralized 2 of the 6 heterologous Envs with an IC50 of greater
than 1:100, and in two cases approaching 1:1000. Interestingly,
205F plasma potently neutralized the 185F Env (red dot on right
point plot), but the reciprocal was not observed (green dot on left
point plot). Thus, Nab in these plasma samples was directed
against predominantly strain-specific targets, but were also capable
of recognizing some common epitopes by approximately two years
after infection.
Selection of Nab resistant ‘escape’ variants for further
study
For 185F, the median Nab IC50 titer for the 0-month Envs was
significantly greater than the contemporaneous Envs at every time
point using a Mann-whitney test (Fig. 1A). Using the criteria of at
least a 100-fold decrease in sensitivity to neutralization compared
to the median of the 0-month Envs, a resistant Env (highlighted in
green) from each time point was selected for in-depth investiga-
tions into Nab escape. At 28-months, three different Nab resistant
Envs were selected because the phylogenetic tree indicated that
multiple lineages of resistance were circulating at this time point
(Fig. S1A). For 205F, the difference between 0-month and
contemporaneous Envs reached significance at only two of the
five time points, although there were Envs at each time point for
which Nab activity was undetectable at the highest dilution of
plasma tested (1:20, Fig. 1B). These Envs, which were often 1000-
fold less sensitive to Nab than the median of the 0-month Envs,
were selected for detailed studies of Nab escape. Two genetically
diverse Envs from distinct lineages were also selected to represent
the 20-month time point in 205F (Fig. S1B).
Early Nab escape involves different escape pathways in
subjects 185F and 205F
We next investigated the adaptations that were responsible for
escape from contemporaneous Nab in 185F and 205F. The 0-
month Envs were potently neutralized by plasma from all
subsequent time points (Fig. 1A and B) and were used to provide
a neutralization sensitive background, which remained more than
95% conserved at the amino acid level with subsequent variants
and could be used to investigate the molecular determinants of
escape for each Nab resistant variant. To do this, two approaches
were used: (i) where sequence changes were limited in the Nab
resistant Env, site-directed mutagenesis was used to introduce
potential escape mutations into the 0-month Env and (ii) where
multiple sequence changes were present in the Nab resistant Env,
larger Env subregions (i.e. V1 to V5, V3 to V5, V1V2, etc.) were
transferred from the Nab resistant Env into the 0-month Env. The
neutralization sensitivity of the chimeric and parental Envs was
then evaluated using plasma contemporaneous with the Nab
resistant Env.
For 185F, the 5-month Nab resistant EnvPB1.1 was chosen to
determine which sequence adaptations were responsible for early
Nab escape. Fig. 3A demonstrates that the chimeras containing
either the region spanning the V1 loop through the end of the V5
domain (V1V5) or the V3 loop through the V5 domain (V3V5)
from the 5-month Env displayed a level of resistance similar to the
parental Env. However, the Nab sensitivity of the chimera
containing the entire V1V2 domain (V1V2) was unchanged
compared to the 0-month Env, despite a K192Q change in V2
(Fig. 3C). We therefore surmised that Nab resistance was heavily
dependent upon the V3V5 subregion, in which there were 3
residues that differed between 0-month EnvPB3.1 and 5-month
EnvPB1.1. These changes were an E335A in the first position of
the a2 helix, and two changes in the V5 region: I459T, which may
also impact CD4 binding, and S463N (Fig. 3C; based on HXB2
numbering). None of these changes altered any of the predicted N-
linked glycosylation sites. To assess its individual contribution to
Nab resistance, each amino acid change was introduced into the 0-
month EnvPB3.1. The V5 mutations I459T and S463N each
independently produced a decrease in neutralization sensitivity,
Table 1. Seroconvertors from ZEHRP that were evaluated for Nab escape.
Subject Viral load
1 Viral load
2 Visit month
Last seroneg
date
First seropos
date
p24 pos
date
a
First sample
date
Estimated days
from infection
b
185F 54,377 91,678 72 6-Aug-02 17-Aug-02 6-Aug-02 17-Aug-02 33
205F 6,125 400 18 1-Mar-03 27-Mar-03 1-Mar-03 27-Mar-03 48
Viral load: RNA copies/ml in plasma at the first sample date
1 and 11months later
2.
Visit month: time period between enrollment into ZEHRP as a discordant couple and the first seropositive visit.
a185F was also p24 doubtful on 17-Aug-02.
b22 days prior to the Ag+ Ab- date for 185F and 205F as described in [38].
doi:10.1371/journal.ppat.1000594.t001
Subtype C HIV-1 Nab Escape
PLoS Pathogens | www.plospathogens.org 3 September 2009 | Volume 5 | Issue 9 | e1000594Figure 1. Cycles of escape from autologous Nab in 185F and 205F. Each panel represents a longitudinal plasma sample where Nab activity
was evaluated for (A) subject 185F (5, 11, 17, 23, and 28 months) or (B) subject 205F (2, 8, 14, 20, and 26 months). Each data point represents the Nab
IC50 titer (shown on the vertical axis on a log10 scale) for a single plasma-Env combination calculated from the virus infectivity curve using the Excel
growth function. The Nab IC50 titers against the 0-month Envs and the contemporaneous Envs are shown for each longitudinal plasma sample
(labeled along the vertical axis), and the horizontal bars indicate the median for each group of Envs. A Mann-whitney analysis was used to test for
statistically significant differences between the Nab sensitivity of the 0-month and contemporaneous Envs, and p-values less than 0.05 were
considered significant. Red dots indicate the Nab IC50 titer for 0-month Env that was used as a background for the chimeras. Green dots indicate the
Nab resistant Envs from each time point that were selected and used to generate the chimeras.
doi:10.1371/journal.ppat.1000594.g001
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level of the V3V5 chimera (Fig. 3B). In contrast, the E335A
change in the a2 helix did not decrease neutralization sensitivity
when introduced by itself into the 0-month Env (Fig. 3B).
Together, these findings indicate that the combined V5 mutations
facilitated neutralization resistance at 5 months, while the changes
in the a2 helix and the V2 loop did not contribute to a detectable
level, at least within the context of the 0-month Env.
A different scenario was observed for early escape in 205F. For
the 2-month escape variant EnvPB2.3, the V1V5 region contained
determinants for Nab resistance (Fig 3D), and this entire region
differed from 0-month EnvPL6.3 by only 3 amino acids (Fig. 3E).
Two changes were located within V1 (an N134S substitution that
introduced a potential N-linked glycosylation site near the N-
terminal V1V2 stem and a Y140P substitution; numbered
according to Fig. S2). In contrast to 185F, introduction of the
two changes in V1 decreased Nab sensitivity by more than 10-fold
in the context of the 0-month Env (Fig. 3D). A third change,
A453T, was located within the b23 region and has the potential to
impact CD4 binding (Fig. 3E). This residue by itself reduced Nab
sensitivity by about 3-fold (Fig. 3D). Thus, for 205F, complete Nab
resistance at 2-months could be achieved by sequence changes in
V1, including addition of a potential N-linked glycan, and a
change in a region involved in CD4 contact [39].
Nab escape in subject 185F involves more complex
determinants over time
Although the mutagenesis studies strongly suggested that the
changes in V5 at 5-months were Nab escape mutations, these
specific residues were not maintained in the subsequent Nab
resistant Envs (Fig. S3). However, the sequence of the V5 domain
continued to evolve over time, suggesting ongoing selective
pressure from Nab. At the last time point analyzed, 28-months,
genetically distinct lineages of Nab escape variants were circulating
(Fig. S1A). The chimera-mapping approach revealed that these
different Env variants had acquired resistance through at least two
distinct mutational pathways (Fig. S4, see bottom 3 panels). More
detailed mapping revealed that for 28-month EnvPL5.1, the V5
domain continued to contribute to Nab resistance (Fig. 4A),
retaining the major escape pathway operative at 5-months. By
contrast, 28-month EnvPL3.1 achieved a similar level of resistance
through an escape pathway that required the gp41 ectodomain in
addition to the cognate V1V5 domain (Fig. 4B). For this Env, the
V1V5 region from the 28-month Env independently conferred
only partial escape onto the 0-month Env, while insertion of the
28-month ectodomain alone had no effect on Nab sensitivity.
Further dissection revealed somewhat surprisingly that the V1V2
domain was a major contributor to Nab resistance in the context
of the gp41 ectodomain, while the V3V5 region in this context did
not appear to contribute to escape. Thus, a cooperative interaction
between the gp41 ectodomain and V1V2 appeared to be
conferring Nab resistance in this Env.
Nab escape in 205F is primarily determined by V1V2 over
time
Having found that changes in the V1V2 and b23 regions drove
early escape from Nab in 205F, we investigated whether this
pattern was maintained over time. Env chimeras were created for
205F using Nab resistant Envs from five time points over a 26-
month follow-up period (Fig. 1B) and evaluated using the same
approach as for 185F. V1V2 was the major determinant of Nab
resistance at all time points analyzed (see Fig. S5). By contrast, the
V3V5 region alone had little effect on resistance, although in
combination with V1V2 it clearly contributed to escape.
In an effort to more precisely define Nab targets and escape
pathways in 205F, B cell hybridomas were generated from viably
frozen PBMC samples collected at 49 months after infection,
which were the earliest available sample of this type. A 0-month
Env (clone PB1.1) was used to screen for neutralizing activity in
the hybridoma supernatants, and two hybridomas produced
monoclonal antibodies (Mabs; 6.4C and 13.6A) that neutralized
this and other 0-month Envs (Fig. 5A and B, respectively).
Surprisingly, the 0-month Envs were not equally sensitive to
neutralization by the two Mabs, despite being very homogeneous
in sequence and potently neutralized by patient plasma (Fig. 1B).
For Mab 6.4C, 0-month EnvPL6.3 was moderately more sensitive
to neutralization than the other two 0-month Envs (Fig. 5A). In
contrast, neutralizing activity for 13.6A was not detectable against
EnvPL6.3, but the other two 0-month Envs were neutralized at
levels similar to those observed with Mab 6.4C (Fig. 5B). The 2-
month EnvPB2.3 was neutralized by both Mabs (Fig. 5A and B).
Neutralizing activity against Envs cloned at 8-months or beyond,
however, was undetectable for both Mabs (Fig. 5A and B),
providing strong evidence that these Mabs could be representative
of those elicited during early infection and that the later Env
variants had developed resistance mutations that protected against
both specificities. An identical pattern was observed for the
purified 6.4C and 13.6A Mabs, with a mean IC50 against the
sensitive 0-months Envs of 39 and 156 ng/ml, respectively (data
not shown). Envs from 8-months and beyond were not neutralized
at 10 mg/ml of either purified Mab (data not shown).
Resistance against Mabs 13.6A and 6.4C involves loss and
gain of predicted glycan addition sites in V1V2
Neutralization of the 205F chimera panel by each Mab
localized differences in sensitivity to the V1V2 domain (data not
shown). Examination of the V1V2 sequences of 0- to 26-month
205F Nab resistant Envs revealed that each one differed in length,
pattern of predicted glycosylation sites, and sequence (Fig. S2).
However, all of the Nab resistant Envs from 8-months and beyond
had acquired a mutation that created a potential glycosylation site
in V2 at position 197 (highlighted in yellow in Fig. S2).
Furthermore, 0-month EnvPL6.3 was the only 0-month Env that
was resistant to 13.6A, and it lacked a potential N-gly site in V1
relative to the other Envs (highlighted in yellow in Fig. S2). Thus,
Figure 2. Moderate neutralization breadth of plasma from
185F and 205F against heterologous 0-month Envs. A single
plasma sample from 185F (23-months) and 205F (20-months) was
evaluated for neutralizing activity against heterologous Envs acquired
during acute/early subtype C infection of six subjects. The Nab IC50 titer
for each plasma-Env combination is shown on the vertical axis on a
log10 scale. Each data point represents a single plasma-Env combina-
tion. Arrows indicate the Nab IC50 titer for the autologous plasma-Env
combination; all other data points represent heterologous Envs. The
plasma sample is indicated below each point plot.
doi:10.1371/journal.ppat.1000594.g002
Subtype C HIV-1 Nab Escape
PLoS Pathogens | www.plospathogens.org 5 September 2009 | Volume 5 | Issue 9 | e1000594Figure 3. Early escape from neutralization in 185F and 205F requires different pathways. Neutralization of escape variants 185F 5-month
PB1.1 (A and B), and 205F 2-month PB2.3 (D) and chimeras or mutants from each of these Envs in the corresponding 0-month Env was evaluated
using contemporaneous plasma. Pseudoviruses were created by expressing each Env with an HIV-1 env-deficient backbone, and their infectivity for
JC53-BL13 (Tzm-bl) cells was evaluated in the absence or presence of serially-diluted patient plasma with luciferase as a quantitative measure. Percent
virus infectivity relative to no test plasma is plotted on the vertical axis; the reciprocal of the plasma dilution is plotted along the horizontal axiso na
log10 scale. Each curve represents one Env against serial plasma dilutions, and error bars represent the standard deviation of at least two
independent experiments using duplicate wells. The legends list the parental Nab resistant Env followed by the chimeric and mutant Envs created in
the 0-month Env background. Amino acid alignments are shown to indicate the sequence differences between the different Envs for 185F (C) and
205F (E). The color of the text corresponds to the curves on the graph. Only regions that contained differences are shown.
doi:10.1371/journal.ppat.1000594.g003
Subtype C HIV-1 Nab Escape
PLoS Pathogens | www.plospathogens.org 6 September 2009 | Volume 5 | Issue 9 | e1000594Figure 4. 185F Nab resistant variants at 28-months utilize distinct escape pathways. Neutralization of 28-month EnvPL5.1 (A) and 28-
month EnvPL3.1 (B) and the chimeric Env pseudoviruses generated from each of these Envs in the 0-month Env background was evaluated using the
28-month plasma sample in JC53-BL13 cells with luciferase as a quantitative measure. Percent virus infectivity is plotted against the reciprocal of the
log10 plasma dilution. Error bars represent the standard deviation of at least two independent experiments using duplicate wells. The panels below
each graph indicate the region that was transferred from the 28-month Nab resistant Env (PL5.1 in A and PL3.1 in B; gray boxes) into 0-month
EnvPL3.1 (white boxes). (C) Amino acid alignment of the V5 region for the 0-month and 28-month Envs.
doi:10.1371/journal.ppat.1000594.g004
Subtype C HIV-1 Nab Escape
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sites determined the pattern of sensitivity to the two Mabs. Fig. 6A
shows the naturally occurring patterns of these predicted glycan
sites that were detected in the early 205F Envs with the positions of
the sites of interest indicated in red (V1) and blue (V2).
To define the effects of these potential glycan addition sites in
V1 and V2 on sensitivity to the two Mabs, both sites were
introduced into 0-month EnvPL6.3, which carried neither
(Fig. 6B). For Mab 13.6A, introduction of the V1 predicted
glycan site into 0-month EnvPL6.3 resulted in a dramatic increase
in neutralization sensitivity (Fig. 6C). In contrast, for 6.4C,
introduction of the V1 predicted glycan produced a moderate
decrease in sensitivity (Fig. 6D). Introduction of the V2 predicted
glycan site into EnvPL6.3, with or without the V1 predicted glycan
site, resulted in strong protection against both Mabs (Fig. 6C and
D). Thus, predicted glycosylation at this site in V2 potentially
tracked with protection against both Mabs (for a summary of
longitudinal Envs and glycan sites see Table 2). These results also
demonstrate that while both Mabs target a V1V2-dependent
epitope, they recognize distinct structures.
The detection of a 0-month Env that was resistant to one of the
Mabs was unexpected given the early timing and high sensitivity
of these Envs to patient plasma. Therefore, the frequency of this
predicted glycan site in V1 during acute/early infection was
investigated using 21 uncloned single genome amplified V1V4
sequences from a p24-positive, antibody-negative sample (1-Mar-
03) and 31 from the 0-month sample (27-Mar-03), which was
antibody positive [38] (see Table 1). These sequences were
combined with the five cloned 0-month Envs from this study, and
a highlighter plot was created using the HIV Database (Fig. S6).
Forty-four out of 57 sequences (77%) were identical throughout
V1V4, and all of these contained the predicted glycan addition
site in V1. Two variants (including EnvPL6.3), both from the
antibody positive time point, carried an identical G to A mutation
that abrogated the predicted V1 glycan addition site. Taken
together, these observations provided strong evidence that the
founder virus, like the 0-month EnvsPB1.1 and PL4.1, carried the
predicted glycan site in V1, and that the mutation in 0-month
EnvPL6.3 arose shortly after transmission, but circulated only
transiently.
Discussion
V5 mediates early escape and could serve as a Nab target
In a previous study, we demonstrated that subtype C infected
seroconvertors mount robust Nab responses against their autolo-
gous viruses during the early stages of infection [15]. Here we have
extended those findings to demonstrate that cycles of viral escape
occur despite potent Nab and that these cycles involve multiple
mechanisms and regions of Env. In subject 185F, early Nab escape
required amino acid substitutions in V5 that were independent of
glycosylation. It is possible that these changes directly altered an
epitope in V5, as this region may be accessible to Nab on the Env
trimer. However, attempts to remove Nab activity with a V5
peptide were unsuccessful, and Env chimeras in which unrelated
Envs were engineered to carry the 185F 0-month V5 sequence
lacked biological activity (data not shown). Thus neither of these
approaches allowed definitive identification of a V5 epitope, and
the latter suggested that the V5 domain itself, or the proximal
region of gp120, likely evolved in concert with adjacent regions of
the protein. Another possibility is that the early changes in V5
created conformational changes that protected a distinct target.
The N-terminal region of V5 has been shown to contain contact
sites for both CD4 and Mab b12 [39], and the escape mutations
could therefore have influenced exposure of epitopes such as the
CD4 binding site. These two alternatives, epitope mutation or
masking, are not mutually exclusive, and it is conceivable that V5
changes could protect from more than one antibody specificity.
This is clearly the case for 205F, where a single amino acid change
in V2 creating a potential glycan addition site resulted in resistance
against two distinct Mabs.
Distinct escape pathways were observed within subject
185F
At later time points in subject 185F, the flexibility of the Env
structure provided alternative mutational pathways to resist
neutralization. Escape pathways in 185F oscillated between
changes localized to the gp120 outer domain (V3V5), and
conformational masking strategies that required interaction
Figure 5. Neutralization profile of 205F Envs by autologous
monoclonal antibody-containing supernatants from B cell
hybridomas 6.4C and 13.6A. Neutralization activity of 6.4C (A)
and 13.6A (B) B cell hybridoma supernatant was evaluated against
pseudoviruses expressing autologous 205F Envs. Three different 0-
months Envs are shown along with the longitudinal panel of Envs.
Percent virus infectivity is plotted against the log10 of the reciprocal
dilution of hybridoma culture supernatant in each graph. Error bars
represent the standard deviation of at least two independent
experiments using duplicate wells. 0-month EnvPB1.1 was used to
screen the hybridomas for neutralization activity. B cell hybridomas
from 205F were generated at 49-months post-infection.
doi:10.1371/journal.ppat.1000594.g005
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PLoS Pathogens | www.plospathogens.org 8 September 2009 | Volume 5 | Issue 9 | e1000594Figure 6. Potential N-linked glycosylation sites in V1 and V2 modulate sensitivity to Mabs. (A) Schematic diagram showing the position
of potential N-linked glycans on the V1V2 sequence of the ‘founder’ 0-month Env sequence (inferred from Fig. S6), the 13.6A-resistant 0-month
EnvPL6.3, and the 6.4C/13.6A-resistant 8-month EnvPB2.3. The absence of the V1 glycan shown in blue was associated with resistance against 13.6A,
while addition of the V2 glycan shown in red was associated with resistance against 13.6A and 6.4C. (B) Potential N-linked glycosylation sites (NXS or
NXT where X is any residue except proline) in V1V2 that were introduced singly or in combination into EnvPL6.3 are shown in blue (V1) or red (V2).
The text color corresponds to the graphs in (C and D). 0-month EnvPL6.3 naturally lacks both sites. Neutralization of 0-month EnvPL6.3 and the site-
directed mutants shown in panel B was evaluated for 13.6A (C) and 6.4C (D) using reduction of luciferase production in JC53-BL13 cells. Percent virus
infectivity is plotted against the log10 reciprocal dilution of hybridoma supernatant. Error bars represent the standard deviation of at least two
independent experiments using duplicate wells.
doi:10.1371/journal.ppat.1000594.g006
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V3V5 was the major determinant at 5-, 14-, and 17-months, and
also in one of the 28-month Nab resistant Envs (see Fig. S4 for
neutralization curves). However, in Envs from two other time
points (11- and 23-months), V3V5 did not independently confer
resistance, but appeared to require contributions from V1V2. In
Nab resistant Envs from three time points (20-, 26-, and 28-
months), the gp120 V1V5 region and the gp41 ectodomain were
both required for resistance. Further mapping for one of these
Envs demonstrated that the V1V2 domain contributed in large
part to this phenotype, but the V3V5 domain in this context did
not. Interestingly, some of the V1V2 domains in subject 185F
contained changes in the predicted glycosylation pattern relative to
the 0-month Env, while others had sequence changes that would
not alter the original glycosylation pattern (Fig. 7A: 5-PB1.1, 11-
PL5.1, 23-PL5.1, and 28-PL5.1).
A novel finding is that Nab resistant Envs at 28-months utilized
distinct Env sub-regions to block the same Nab pool. This
provided a striking example of convergent, intra-patient evolution
during early infection. One pathway was heavily dependent on the
V5 domain, while the other exhibited V1V2 and gp41 co-
dependence. The V5 domains of these two Envs contained the
same predicted glycosylation shift (Fig. 7A: green and white
spheres in 28-PL3.1 and 28-PL5.1) but differed in primary amino
acid sequence (Fig. 4C). This raises the possibility that the V5-
dependent Env contained mutations that directly confer epitope
escape, while the V1V2-dependent Env retained the target but
escaped through indirect mechanisms. In addition, both V1V2
and the regions flanking V5 are proximal to the CD4 binding site
and could therefore alter its exposure, as has been proposed for
changes in V2 and V5 in the context of a SHIV infection [30].
Thus, in examining a single subject in great detail, we have
uncovered remarkable flexibility in the pathways of viral escape
during early infection. These results further highlight how the
plasticity of the Env hyper-variable domains coupled with complex
conformational interactions could provide numerous options for
escape.
Different pathways were observed between subjects
In contrast to subject 185F, Nab escape in 205F was driven
predominantly by changes in the V1V2 domain (Fig. 8A and B). A
preference for potential glycan shifts in V1V2 became evident
from the spatial representation of gp120, where in the 14-month
Env, four predicted glycosylation site changes are observed in V1
alone (Fig. 8A: green and white spheres in Env 14-PB5.4). The
importance of V1V2 for escape was further illustrated by the
demonstration that two predicted glycan sites, one in V1 and one
in V2, influenced neutralization by two Mabs derived from this
same subject. Thus, this study is the first to identify specific
mutations that confer autologous Nab resistance at the single
antibody level. This made possible several observations that were
not apparent from polyclonal plasma. First, a single substitution
can confer resistance against multiple antibody specificities within
an individual. While we did not formally show that glycosylation at
the substituted site was responsible for resistance against Mabs
6.4C and 13.6A, there is strong evidence from other studies to
support that this is the case. Second, different pathways of escape
also operate at the single antibody level. Resistance against 13.6A
could be achieved either by addition of the predicted glycan site in
V2 or by loss of the predicted glycan site in V1. Interestingly, only
the modification of V2 was retained in subsequent escape variants,
suggesting that it could have been more advantageous in terms of
escape and or maintenance of replication fitness. Third, mutations
that confer escape from multiple monoclonal antibody specificities
do not necessarily confer escape from the entire polyclonal Nab
milieu in plasma. The V2 modification in the 8-month Env
conferred complete resistance against 6.4C and 13.6A at 10 mg/
ml, but only partial escape from patient plasma (Fig. S5 and data
not shown). This finding suggests that escape determinants
mapped against plasma will only reflect the dominant Nab
specificities that are present at relatively high concentration (able
to inhibit virus infectivity at greater than a 1:100 dilution in our
assay), but other lower titer Nab specificities could also drive
escape mutations. The relative contributions of different antibody
specificities in plasma will undoubtedly vary among subjects, and
potentially even within a subject over time, resulting in the need
for customized escape pathways that are driven by each dominant
Nab response. Thus, to derive a complete picture of autologous
Nab and escape, it will be necessary to recover and characterize
individual Mabs with different specificities, as was done here and
recently by others to dissect the B cell response in subjects with
neutralization breadth [9]. These studies demonstrate how the
HIV-1 subtype C Env is uniquely equipped to respond to the
current immune response of each individual host by adjusting its
pathways of escape.
Temporal properties of escape from autologous Mabs
The V2-based mutation that conferred resistance against 6.4C
and 13.6A appeared during the first eight months of infection;
however, 13.6A and 6.4C were recovered from memory B cells
circulating 41 months later. As such, it was not possible to
determine whether related B cells were circulating during early
infectionin205F. TheV1-basedchange that conferred resistance
against 13.6A was present at 0-months (at which time the subject
was seropositive), but only transiently. If this mutation occurred
in response to immune pressure from 13.6A, then this antibody
must have been present within ,48 days from the calculated
time of infection. Indeed we have observed very low level
neutralizing activity (IC50=,1:40) in the 0-month plasma of
205F against 0-month Envs [15] and (data not shown), consistent
with this concept. While others have observed that the very early
antibody response (within the first ,40 days after infection)
lacks neutralizing activity and is directed predominantly
against gp41 [40], our findings raise the possibility that viral
neutralization and escape could occur earlier than previously
thought. Individual Mabs, derived from B cells early in infection
Table 2. Summary of Mab neutralization data for 205F Envs.
Env V1 glycan V2 glycan 13.6A 6.4C
0-month PB1.1 + 2 ++
0-month PL4.1 + 2 ++
2-month PB2.3 + 2 ++
0-month PL6.3 - V1gly + 2 ++
0-month PL6.3 222 +
0-month PL6.3 - V2 gly 2 + 22
0-month PL6.3 - V1V2gly ++22
8-month PB2.3 ++22
14-month PB5.4 +shift + 22
20-month PB2.2 ++22
20-month PB5.2 ++22
26-month PB2.2 +shift +shift 22
doi:10.1371/journal.ppat.1000594.t002
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PLoS Pathogens | www.plospathogens.org 10 September 2009 | Volume 5 | Issue 9 | e1000594Figure 7. Nab escape in 185F involves multiple pathways. (A) A 3-dimensional representation of the gp120 amino acid sequence for a
different longitudinal Nab escape variant Env is shown in each panel. The time point and clone is indicated in each panel. The blue gp120 backbones
were generated by homology modeling of the 0-month Env sequence onto the CD4-liganded HIV-1 YU-2 gp120 structure [54], with modeled V1V2
and V3 loops as described previously [25]. Red indicates amino acid changes relative to the 0-month Env sequence. Spheres indicate changes in
potential N-linked glycosylation sites (green=loss, white=gain). (B) Schematic representation of the Env domains contributing to Nab escape at
each time point. Yellow indicates that a single domain had a major effect on Nab resistance; gray indicates that a particular domain contributed
partially to Nab resistance. For more detail, see Fig. S4.
doi:10.1371/journal.ppat.1000594.g007
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this initial Nab activity. It will therefore be important to
determine whether Nab activity and viral escape is present in
other subtype C infected subjects at very early time points, as well
as whether early escape mutations are associated with decreased
viral fitness.
Figure 8. Nab escape in 205F is V1V2-dependent. (A) A 3-dimensional representation of the gp120 amino acid sequence for a different
longitudinal Nab escape variant Env is shown in each panel. The time point and clone is indicated in each panel. The blue gp120 backbones were
generated by homology modeling of the 0-month Env sequence onto the CD4-liganded HIV-1 YU-2 gp120 structure [54], with modeled V1V2 and V3
loops as described previously [25]. Red indicates amino acid changes relative to the 0-month Env sequence. Spheres indicate changes in a potential
N-linked glycosylation sites (green=loss, white=gain). (B) Schematic representation of the Env domains contributing to Nab escape at each time
point. Yellow indicates that the domain that had a major effect on Nab resistance; gray indicates the domain that made a minor contribution to Nab
resistance. For more detail, see Fig. S5.
doi:10.1371/journal.ppat.1000594.g008
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Importantly in this study, not all sequence changes were linked
directly with Nab escape. For example, one of the first sequence
changes that was present in the 185F 5-month Env was a substitution
in the first position of the a2 helix (E335A); however, this change did
not alter Nab sensitivity to contemporaneous plasma when introduced
into the 0-month Env. Reversal of this mutation (A335E) in the 5-
month escape variant also did not increase its sensitivity to autologous
Nab (Murphy et al., in preparation). The 205F Nab escape variants
also exhibited variation in the a2 helix beginning at 14-months, but
again this region did not appear to contribute independently to Nab
escape. These findings support that a2 was not targeted directly by
Nab in these instances, despite ongoing sequence evolution. The a2
helix has been linked to autologous and heterologous Nab sensitivity of
subtype C Envs from Zambia, South Africa, and India by our group
and others [23,25,41]. However, its exact role(s) in Nab sensitivity or
escape remains undetermined [23,25]. We have speculated that thea2
helix plays an ancillary role in Nab escape, and perhaps participates in
maintenance of the tertiary structure of the gp120 outer domain or the
quaternary structure of the trimer [25,42]. The findings presented
here support our earlier findings, but do not rule out the possibility
that the a2 helix is targeted by Nab in some instances, or by low titer
Nab specificities. Studies are ongoing in our laboratory to more
precisely define the role of changes in the a2 helix in the context of
autologous Nab. In addition to the a2 helix, sequence variation was
observed in V1V2, V5, and other regions of the outer domain in
both 185F and 205F Envs (Fig. 9A and B, respectively). However, in
185F, the V3V5 region had the strongest effect on Nab resistance,
while in 205F V1V2 was the major determinant. A companion study
of four subtype C infected seroconvertors and our own previous
study of subtype C chronically infected subjects reported consistent
findings, in that V1V2 was commonly involved in Nab escape, but to
varying degrees [24] and (Moore et al., in press). Importantly, the
combined biological results and spatial analysis of these two subjects
demonstrate how the perpetual flexibility of the V1V2 and V5
domainsprovidesaformidabledefenseagainst Nab.This could bedue
in part to their ability to simultaneously mask multiple epitopes
through limited changes, but may also involve direct escape.
Mechanistic properties of different escape pathways
Although these studies were conducted on a small number of
subjects, it is still beneficial to work toward developing a
mechanistic model that can explain the underlying complexity of
escape pathways between and within subjects. The results
presented here provide the basis for such an endeavor. First, the
escape pathways observed here appear to define Nab resistance
through a combination of direct and indirect mechanisms. Direct
epitope changes may be sufficient in the setting of limited antibody
specificities, such as during the early phase of infection, while
indirect ‘masking’ or cooperative mechanisms may be required
later when multiple antibody specificities are circulating. However,
it will be important to expand and confirm these studies by
characterizing Nab escape in additional subjects. The frequency,
timing, and underlying basis for convergent escape pathways
within a subject will require further investigation, as will the
significance of regions of subtype C Env that appear to be under
positive selection but do not contribute directly to escape from
plasma Nab. Lastly, it will be important to determine if different
escape pathways share any common conformational basis or point
to specific regions of the Env that should be incorporated into or
excluded from vaccine immunogens.
Methods
Ethics statement
Informed consent and human subjects protocols were approved
by the Emory University Institutional Review Board, and the
Figure 9. Sequence variation occurs in similar regions of Env in 185F and 205F. A 3-dimensional representation of the sequence variation
in gp120 over time in 185F and 205F is shown in panels (A and B), respectively. The gp120 backbones were generated by homology modeling of the
0-month Env sequences of 185F and 205F onto the CD4-liganded HIV-1 YU-2 gp120 structure [54], with modeled V1V2 and V3 loops as described
previously [25]. Blue to green to red indicates degree of sequence conservation (high to low) within the alignment.
doi:10.1371/journal.ppat.1000594.g009
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Committee. Written Informed consent was obtained from human
subjects.
Study subjects
The Zambia Emory HIV Research Project (ZEHRP) was
established in Lusaka in 1994 to provide voluntary HIV-1 testing
and counseling, long-term monitoring, and health care to
cohabiting heterosexual couples. Details of the cohort have been
described elsewhere [43]. Briefly, HIV-discordant couples enrolled
in studies of transmission are monitored for seroconversion of the
negative partner at three-month intervals, at which time the
participants also receive preventative counseling and condoms.
Banked plasma samples from seronegative partners are tested for
p24 antigen by ELISA to identify individuals with acute infection
[38]. The two subtype C infected seroconvertors studied here were
participants in this cohort and were identified as p24 antigen
positive and seropositive by rapid test and western blot, as
described in [38,44]. Plasma viral loads were determined using the
Roche Amplicor HIV-1 assay. None of the subjects received
antiretroviral therapy during the evaluation period.
Amplification and cloning of HIV-1 env genes
Conditions for single genome PCR amplification of full-length
gp160 (plus Rev, Vpu, and partial Nef coding sequences) from the
genomic DNA of uncultured peripheral blood mononuclear cells
and cDNA from plasma have been described previously [38,44].
The viral env amplicons were directionally T/A cloned into the
CMV-driven expression plasmid pcDNA3.1-V5HisTOPO-TA
and screened for biological function as pseudoviruses following
co-transfection with an Env-deficient subtype B proviral plasmid
(SG3Denv) into 293T cells [45]. Seventy-two hours later,
supernatant was collected and used to infect JC53-BL13 (Tzm-
bl) cells. At 48 hours post-infection, b-gal staining was performed
and each well was scored positive or negative for blue foci.
Sequence analysis
DNA sequencing of env genes was carried out by Lone Star Labs,
Inc. (Houston, TX) utilizing the ABI PrismH Automated DNA
sequencer 377XL and Big Dye
TM Terminator Ready Reaction
Cycle Sequencing Kit. Nucleotide sequences were edited and
assembled using Sequencher v4.7, translated using Se-Al v2.0all,
and nucleotide or amino acid alignments were created using Clustal
W v1.83. Neighbor joining phylogenetic trees were generated by
Clustal W v1.83 using gap-stripped nucleotide sequences of the
complete env gene, and reliability of branching orders was assessed
by bootstrap analysis using 1,000 replicates. Trees were visualized
usingNJPlot.Alignedsequenceswereimported intotheHighlighter
tool to analyze viral diversity (http://www.hiv.lanl.gov/content/
sequence/HIGHLIGHT/highlighter.html). Sequences have been
deposited into Genbank under the accession numbers GQ485312-
GQ485447.
Neutralization assay
Patient plasma samples were evaluated for neutralizing antibody
activity against virions pseudotyped with autologous patient-
derived viral Envs using a single round reporter assay described
previously [17,45]. Briefly, JC53BL-13 (Tzm-bl) cells were plated
and cultured overnight. Two thousand infectious units of each
pseudovirus was combined with five-fold dilutions of heat-
inactivated patient plasma and incubated for 1 hour at 37uC.
Normal heat-inactivated human plasma was added as necessary to
maintain a constant overall concentration. The virus-Ab mixture
was then added to JC53BL-13 cells, and after two days, the cells
were lysed, and the luciferase activity of each well was measured
using a luminometer. Background luminescence was determined
in uninfected wells and subtracted from all experimental wells.
Percent infectivity was calculated by dividing the number of
luciferase units at each plasma dilution by the value in the well
containing no test plasma. The dilution of patient plasma that
inhibited 50% of virus infectivity (IC50 titer) was determined using
the Microsoft Excel 2004 for Mac Growth Function. Each
experiment was performed independently at least twice with
duplicate wells.
Construction of chimeric Envs
Chimeric Envs were constructed using a domain exchange
strategy that has been described previously [24,25]. The primer
sequences and their HXB2 locations are shown below. A PCR
screen was performed to identify transformants in which the
fragments ligated together in the correct orientation using forward
primer EnvA and the reverse primer that was used to amplify the
exchangeddomain.Coloniesthat werepositivebyPCRscreenwere
inoculated into LB-Ampicillin broth for overnight cultures, and the
plasmid was prepared using the QIAprep Spin Miniprep Kit. Env
chimeras were then screened for biological function as described
above. For chimeras that produced functional Env pseudotypes, the
plasmids were re-transfected into 293T cells on a larger scale to
produce a working pseudotype virus stock. Transfection superna-
tants were collected at 72 hours post-transfection, clarified by low
speed centrifugation, aliquoted into 0.5 ml or less portions, and
stored at 280uC. The titer of each pseudovirus stock was
determined by infecting JC53-BL13 cells with 5-fold serial dilutions
of virus as described previously. All Env chimeras were confirmed
by nucleotide sequencing of the entire env gene.
For subject 185F V1V5 domain amplification, forward primer 59-
catgtgtaaagttgaccccac-39 (HXB2 nt 6577 to 6597) and reverse
primer 59-atctcctcctccaggtctgaa-39 (HXB2 nt 7646 to 7626); V1V2
domain amplification, forward primer 59-catgtgtaaagttgaccccac-39
(HXB2 nt 6577 to 6597) and reverse primer 59-tgttacggctgaggtat-
taca-39 (HXB2 nt 6830 to 6810); V3V5 domain amplification,
forward primer 59-cccaacaataatacaaggaaa-39 (HXB2 nt 7119 to
7139)andreverseprimer59-atctcctcctccaggtctgaa-39(HXB2nt7646
to 7626); ecto domain amplification, forward primer 59-agagcagtgg-
gaataggagct-39 (HXB2 nt 7755 to 7775) and reverse primer 59-
tatataccacagccatcttga-39 (HXB2 nt 8270 to 8250); HR2 domain
amplification, forward primer 59-tgcaccactaatgtgccttgg-39 (HXB2 nt
8034 to 8054) and reverse primer 59-tatataccacagccatcttga-39
(HXB2 nt 8270 to 8250); V5 domain amplification, forward primer
59- taaatcaaatatcacaggact-39 (HXB2 nt 7559 to 7579) and reverse
primer 59-atctcctcctccaggtctgaa-39 (HXB2 nt 7646 to 7626).
For subject 205F, V1V5 domain amplification, forward primer
59-gggatcaaagcctaaaaccat-39 (HXB2 nt 6557 to 6579) and reverse
primer 59-cggtctgaatgtctctgt-39 (HXB2 nt 7634 to 7617); V1V2
domain amplication, forward primer 59-gggatcaaagcctaaaaccat-39
(HXB2 nt 6557 to 6579) and reverse primer 59-aataatgtatag-
gaattggatc-39 (HXB2 nt 6876 to 6855); V3V5 domain amplifica-
tion, forward primer 59-tgcacaagacccaacaataat-39 (HXB2 nt 7110
to 7130) and reverse primer 59-cggtctgaatgtctctgt-39 (HXB2 nt
7634 to 7617).
The 0-month Env backbones (minus the target domains) with
pcDNA3.1 vector sequences were PCR amplified using primers
that anneal to conserved regions adjacent to the target domain
primers. These primers amplify away from the target domains. A
59 phosphate group (Phos) was added to these primer sets during
synthesis to facilitate ligation to the target domain amplicons. The
primer sequences and their HXB2 locations were as follows:
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Phos-atgagggacaattggagaagtg-39 (HXB2 nt 7647 to 7668) and
reverse primer 59-Phos-gctttaagctttgatcccataaac-39 (HXB2 nt 6576
to 6553); V1V2 domain backbone, forward primer 59-Phos-
caagcctgtccaaaggtctct-39 (HXB2 nt 6831 to 6851) and reverse
primer 59-Phos-gctttaagctttgatcccataaac-39 (HXB2 nt 6576 to
6553); V3V5 domain backbone, forward primer 59-Phos-atgagg-
gacaattggagaagtg-39 (HXB2 nt 7647 to 7668) and reverse primer
59-Phos-ccttacacacacaatttctac-39 (HXB2 nt 7118 to 7098); ecto-
domain backbone, forward primer 59-Phos-aagatatttataatgatagta-
39 (HXB2 nt 8271 to 8291) and reverse primer 59-Phos-
tttttctctctccaccactctcc-39 (HXB2 nt 7754 to 7732); V5 domain
backbone, forward primer 59-Phos-atgagggacaattggagaagtg-39
(HXB2 nt 7647 to 7668) and reverse primer 59-Phos-catgt-
tatgtttcctgcaatg-39 (HXB2 nt 4527 to 4507).
The PCR amplification conditions for the 0-month Env
backbones were 1 cycle of 95uC for 3 min; 35 cycles of 95uC for
1 min, 50uCt o6 0 uC for 30 s (the optimal annealing temperature
was determined for each primer set), 72uC for 10 min; 1 cycle of
72uC for 15 min; and storage at 4uC. The amplification conditions
for the target domains were the same, except the extension time at
72uC was reduced to 30 s. The 25 ml PCR mixtures contained
50 ng of each primer, 10 ng of the plasmid template, 2.5 mM
MgCl2, 0.2 mM deoxynucleoside triphosphate, and 16 reaction
buffer. PfuUltra II DNA polymerase (Stratagene) was used to
generate the blunt-ended PCR amplicons, which were digested
with DpnI to remove contaminating template DNA and gel
purified from an agarose gel using the QIAquick Gel Extraction
Kit (QIAGEN) prior to ligation. Each target domain DNA
fragment was then ligated to the purified 0-month env backbone to
produce a chimera using T4 DNA ligase (5 U/ml; Roche) at 4uC
overnight. The ligation reaction mixture (usually one-third of the
volume) was transformed into maximum-efficiency XL2-Blue
Ultracompetent cells (1610
9 CFU/mg DNA; stratagene) so that
the DNA volume did not exceed 5% of the cell volume. The entire
transformation was plated onto LB-ampicillin agar plates,
generally resulting in 10 to 50 colonies per ligation reaction.
PCR-based site-directed mutagenesis
To investigate whether individual amino acid sequence
differences contributed to the neutralization resistant phenotype,
PCR-based site-directed mutagenesis was used to introduce an
amino acid change as described previously [24]. Briefly, a set of
primers was used that each had either the wildtype or mutated
sequence. The primer sequences and their HXB2 locations are
shown below, where the substituted nucleotides are underlined. All
mutants were confirmed by sequencing the entire env gene.
The PCR amplification conditions were 1 cycle of 95uC for
1 min; 18 cycles of 95uC for 50 s, 60uC for 50 s, 68uC for 8 min;
and 1 cycle of 68uC for 7 min. The 25-ml PCR mixtures contained
63 ng of each primer, 5 ng of the plasmid template, 0.2 mM
deoxynucleoside triphosphate, and 16reaction buffer. PfuUltra HF
DNA polymerase (Stratagene) was used, amplicons were digested
with DpnI to remove contaminating template DNA, and 2 ml was
transformed into maximum-efficiency XL10-Gold ultracompetent
cells (5610
9 CFU/mg DNA; Stratagene). Half of the transforma-
tion was plated onto LB-ampicillin agar plates, generally resulting
in 10 to 50 colonies per reaction. All mutants were confirmed by
sequencing the entire env gene.
185F E335A forward primer: 59-gcatattgtaacattagtgcacagacatg-
gaatgac-39
185F E335A reverse primer: 59-gtcattccatgtctgtgcactaatgttacaa-
tatgc-39 (HXB2 nt 7244 to 7209)
185F I459T forward primer: 59-ctattgacacatgatgggacatatgcaaa-
tagcaat-39
185F I459T reverse primer: 59-attgctatttgcatatgtcccatcatgtgt-
caatag-39 (HXB2 nt 7610 to 7575)
185F S463N forward primer: 59-cacatgatgggatatatgcaaataacaa-
taatacaacatta-39
185F S463N reverse primer: 59-taatgttgtattattgttatttgcatatatcc-
catcatgtg-39 (HXB2 nt 7622 to 7582)
185F V518M forward primer: 59-gggaataggagctatgttccttgggtt-
cttggg-39
185F V518M reverse primer: 59-cccaagaacccaaggaacatagctcc-
tattccc-39 (HXB2 nt 7795 to 7763)
205F V1mut forward primer: 59-gctgtagcaattatagcaattgtaatga-
tacc-39
205F V1mut reverse primer: 59-ggtatcattacaattgctataattgcta-
cagc-39 (HXB2 nt 6645 to 6614)
205F V2mut forward primer: 59-gcctaatgatagtaactctagtgagtata-
tatta-39
205F V2mut reverse primer: 59-taatatatactcactagagttactatcat-
taggc-39 (HXB2 nt 6812 to 6779)
Generation of B cell hybridomas
Human B cell hybridomas were generated from viable frozen
PBMC samples from subject 205F based on a protocol of EBV
immortalization of peripheral blood B cells as described previously
[46,47,48]. This protocol includes immortalization of pre-selected
(CD22+, IgM2, IgD2, IgA2) memory B cell populations that are
cultured in medium supplemented with immunostimulatory CpG
sequences and irradiated allogeneic PBMC, as described in
[49,50,51]. EBV-transformed B cell cultures were screened for
Mabs that neutralized the 205F 0-month Env and that bound
envelope glycoproteins by ELISA [52,53]. The method used to
screen for neutralizing Mabs is a modification of the Tzm-bl
(JC53-BL13) luciferase reporter cell assay originally developed by
Wei et al. [15,17,24,45]. EBV-transformed B cell hybridomas with
neutralizing activity were cloned in the presence of CpG and
irradiated PBMC. Culture supernatant was collected from the two
hybridomas, 6.4C and 13.6A, and used in the neutralization
studies to map targets and escape.
Supporting Information
Figure S1 Phylogenetic tree of longitudinal 185F and 205F Envs.
A. A neighbor-joining tree was generated using Clustal W v.1.83 for
OSX using the entire env nucleotide sequence of 103 185F Envs
from 11 time points and 8 Envs from the donor partner 185M at 0-
months. A consensus C sequence was used to root the tree. An
asterisk indicates a bootstrap greater than 80. Closed symbols
indicate Envs from plasma; open symbols indicate Envs from
uncultured PBMC DNA. Colors from warm to cool indicate
longitudinal time points; squares indicate Envs from the donor
partner. A red arrow indicates the two 0-month Envs (PL3.1 and
PB3.1) that were used as a background for chimeras and mutants;
black arrows indicate Nab resistant Envs used for domain exchange
into the chimera. Shadedgray boxesindicate3 distinct phylogenetic
lineages that included 28-month escape variants. B. A neighbor-
joining tree wasgeneratedusingClustal Wv.1.83forOSXusingthe
entire env nucleotide sequence of 34 205F Envs from 7 time points
and 5 Envs from the donor partner 205M at 0-months. A consensus
C sequence was used to root the tree. An asterisk indicates a
bootstrap greater than 80. Closed symbols indicate Envs from
plasma; open symbols indicate Envs from uncultured PBMC DNA.
Colors from warm to cool indicate longitudinal time points; squares
indicates Envs from the donor partner. A red arrow indicates the 0-
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chimeras; black arrows indicate Nab resistant Envs used for domain
exchange into the chimera. Shaded gray boxes indicate 2 different
Nab resistant Envs from the 20-month time point.
Found at: doi:10.1371/journal.ppat.1000594.s001 (0.79 MB PDF)
Figure S2 Amino acid sequence alignment for 205F Envs. Three
0-month Nab sensitive Envs and six Nab resistant Envs from
subsequent time points were selected for study from 32 Envs. Env
clones are indicated by the time point (in months), source
(PB=PBMC DNA or PL=plasma), and clone number. Sequences
are shown in reference to the 0-month EnvPB1.1, with amino acid
differences indicated by the letter, and deleted residues indicated by
a dot.Domains thatweretransferred intothe0-month Envtocreate
chimeras areasfollows: V1V5 (blue,gray and green;HXB2 nt6557
to 7634),V1V2 (blue;HXB2 nt6557 to 6876),V3V5(green; HXB2
nt 7110 to 7634). Major Env domains are indicated above the
region, and the a2 helix is underlined. Two potential N-linked
glycan addition sites of interest in V1 and V2 (NXS or NXT where
X is any residue but proline) are highlighted yellow.
Found at: doi:10.1371/journal.ppat.1000594.s002 (0.37 MB PDF)
Figure S3 Amino acid sequence alignment for 185F Envs. Two
0-month Nab sensitive Envs and ten Nab resistant Envs from
subsequent time points were selected for study from 58 Envs. Env
clones are indicated by time point (in months), the source
(PB=PBMC DNA or PL=plasma), and clone number. Sequenc-
es are shown in reference to the 0-month Env PL3.1, with amino
acid differences indicated by the letter, and deleted residues
indicated by a dot. Domains that were transferred into the 0-
month Env to create chimeras are as follows: V1V5 (blue, gray,
and green; HXB2 nt 6577 to 7646), V1V2 (blue; HXB2 nt 6577 to
6810), V3V5 (green; HXB2 nt 7119 to 7646), gp41 ectodomain
(yellow; HXB2 nt 7755 to 8270).
Found at: doi:10.1371/journal.ppat.1000594.s003 (0.50 MB PDF)
Figure S4 The major determinants of Nab resistance in 185F
Envs change over time. Neutralization of 185F parental and
chimeric Env pseudoviruses was evaluated using longitudinal
plasma samples that are indicated in each panel. Each plasma
sample was contemporaneous with the Nab resistant Env, and
neutralization sensitivity was evaluated in JC53-BL cells using
luciferase as a quantitative measure. Percent virus infectivity is
plotted against the reciprocal of the log10 reciprocal plasma
dilution. Error bars represent the standard deviation of at least two
independent experiments using duplicate wells. All chimeras were
created in the 0-month EnvPL3.1 background (red lines). In the
legend, the parental Env clones are indicated, followed by each
chimera that contains the indicated region from the Nab resistant
Env in the 0-month Env. ‘ecto’ stands for the gp41 ectodomain.
Found at: doi:10.1371/journal.ppat.1000594.s004 (0.22 MB PDF)
Figure S5 The major determinants of Nab resistance in 205F
Envs are in V1V2. Neutralization of 205F parental and chimeric
Env pseudoviruses was evaluated using longitudinal plasma
samples that are indicated in each panel. Each plasma sample
was contemporaneous with the Nab resistant Env, and neutral-
ization sensitivity was evaluated in JC53-BL cells using luciferase
as a quantitative measure. Percent virus infectivity is plotted
against the reciprocal of the log10 reciprocal plasma dilution.
Error bars represent the standard deviation of at least two
independent experiments using duplicate wells. All chimeras were
created in the 0-month EnvPL6.3 background (red lines). In the
legend, the parental Env clones are indicated, followed by each
chimera that contains the indicated region from the Nab resistant
Env in the 0-month Env.
Found at: doi:10.1371/journal.ppat.1000594.s005 (0.14 MB PDF)
Figure S6 Highlighter plot showing nucleotide mismatches in
the gp120 V1V4 region for 205F Envs. Single genome amplified,
uncloned V1V4 sequences derived from the 1-Mar-03 sample
(n=21) or the 27-Mar-03 sample (n=31) from 205F and V1V4
sequences from single genome amplified cloned Envs from the 27-
Mar-03 sample (n=5) were subjected to Highlighter analysis
(www.hiv.lanl.gov). Ticks represent mismatched bases compared
to the master sequence listed at the top. The three 0-month Envs
that were analyzed for neutralization by 6.4C and 13.6A in Fig. 11
are boxed in red. PB=uncultured PBMC DNA; PL=plasma.
The G.A mutation (diamonds) located near the beginning of the
sequence represents the loss of a potential N-gly site in V1 that
tracks with resistance against 13.6A.
Found at: doi:10.1371/journal.ppat.1000594.s006 (0.11 MB PDF)
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